Colossal Biosciences Expands Bluebuck De-Extinction Into Broader Conservation Tech Platform

Colossal Biosciences, a de-extinction and conservation biotech company, used a series of LinkedIn posts this week to spotlight the bluebuck as its latest species initiative. The extinct South African antelope, last seen around 1800, is being positioned as both a de-extinction target and a testbed for conservation genomics technologies.

The company says it has assembled a high-quality bluebuck genome and is developing novel assisted reproductive tools for antelope, including ovum pick-up and IVF. These technologies are framed as having applications beyond species revival, potentially helping address habitat fragmentation and declining genetic diversity in living antelope populations across Africa.

Colossal is also reinforcing a broader strategy that ties high-profile projects like mammoths and dodos to present-day biodiversity goals. Chief Animal Officer Matt James highlighted that a substantial share of the firm’s work is focused on protecting currently endangered wildlife and tackling the biodiversity crisis.

For investors, the latest messaging underscores a platform approach built around genomics, reproductive biotech, and conservation tools rather than single-species showcases. If Colossal can convert these capabilities into scalable services and partnerships with governments, NGOs, and conservation groups, it could expand its addressable market in wildlife genetics and biodiversity technology.

At the same time, the company acknowledges that timelines, regulatory pathways, and monetization models for de-extinction and related conservation applications remain uncertain. Overall, the week’s communications strengthen Colossal’s positioning as a leading player in de-extinction while emphasizing nearer-term conservation relevance and potential funding channels beyond traditional venture capital.